PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Investors

Press Releases

All Releases
View Summary BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
Apr 16, 2014
PDF 8.2 KB Add to Briefcase
View Summary FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets
Apr 14, 2014
PDF 15.6 KB Add to Briefcase
View Summary BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors
Mar 21, 2014
PDF 10.2 KB Add to Briefcase
View Summary BioMarin Announces Pricing of Public Offering of Common Stock
Mar 5, 2014
PDF 10.8 KB Add to Briefcase
View Summary BioMarin Announces Public Offering of Common Stock
Mar 4, 2014
PDF 10.1 KB Add to Briefcase
View Summary BioMarin to Present at the Barclays Global Healthcare Conference in Miami
Mar 4, 2014
PDF 7.3 KB Add to Briefcase
View Summary BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results
Feb 26, 2014
PDF 39.8 KB Add to Briefcase
View Summary BioMarin to Present at the Cowen Healthcare Conference in Boston
Feb 25, 2014
PDF 7.2 KB Add to Briefcase
View Summary BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome
Feb 20, 2014
PDF 59.1 KB Add to Briefcase
View Summary BioMarin to Present at Two Upcoming Investor Conferences in New York
Feb 19, 2014
PDF 7.5 KB Add to Briefcase
View Summary BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results
Feb 17, 2014
PDF 13.8 KB Add to Briefcase
View Summary BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome
Feb 14, 2014
PDF 64.7 KB Add to Briefcase
View Summary BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network's 10th Annual WORLDSymposium(TM)
Feb 13, 2014
PDF 106.2 KB Add to Briefcase
View Summary BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)
Feb 11, 2014
PDF 12.5 KB Add to Briefcase
View Summary BioMarin to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast on Monday, March 3 at 8:00 a.m. ET
Feb 5, 2014
PDF 8.1 KB Add to Briefcase
View Summary BioMarin Announces Agreement With Repligen for Pre-clinical Compounds
Jan 21, 2014
PDF 8.6 KB Add to Briefcase
View Summary BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia
Jan 14, 2014
PDF 10.3 KB Add to Briefcase
View Summary American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU)
Jan 13, 2014
PDF 13.5 KB Add to Briefcase
View Summary BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
Jan 13, 2014
PDF 10.3 KB Add to Briefcase
View Summary Jean-Jacques Bienaime, CEO of BioMarin, to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Jan 7, 2014
PDF 7.4 KB Add to Briefcase
Showing 1-20 of 290 Page: 1 2 3 4 5 ... 15  Next 20
Add to Briefcase = add release to Briefcase